New drug Keveyis (dichlorphenamide) received FDA approval on August 10, 2015. It is the first prescription approved to treat a rare genetic disorder known as periodic paralysis.
Periodic paralysis can be triggered by too much or too little potassium in your blood (hyperkalemic or hypokalemic), and involves periods of muscle weakness or paralysis. It is estimated to affect only 5,000 people in the United States; according to the Periodic Paralysis International, hypokalemic periodic paralysis (caused by too little potassium) is estimated to occur in only 1 per 100,000 people. See More